Abbott Laboratories stock trades 26.5 percent below its yearly high

Published on 10/06/2026 at 17:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock was at USD 99.33 on October 6, 2026, 26.5 percent below its yearly high. Second-quarter sales rose 13.0 percent to USD 12.593 billion.

Bauhaus MEDTECH DIAGNOSTIK Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 Bauhaus-Poster MEDTECH DIAGNOSTIK Geometrie Primärfarben Rot Gelb Blau Schwarz Kreise Dreiecke, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) was trading at USD 99.33 on the NYSE on October 6, 2026 at 11:23 a.m. ET, placing the share 26.5 percent below its 52-week high of USD 135.13. The next major checkpoint is Abbott's third-quarter report scheduled for October 21, 2026, before the market opens.

Second-quarter growth sets the baseline

According to Trivano, Abbott reported second-quarter 2026 sales of USD 12.593 billion for the period ended June 30, 2026. Reported sales increased 13.0 percent from the prior-year quarter, while comparable sales grew 4.8 percent.

The earnings mix was more uneven. Abbott delivered adjusted diluted EPS of USD 1.31, up 4.0 percent from USD 1.26 in the second quarter of 2025, while GAAP diluted EPS was USD 0.53 versus USD 1.01 a year earlier. The company raised full-year 2026 adjusted EPS guidance to USD 5.45-5.60 from USD 5.38-5.58, according to Trivano on July 16, 2026.

Diagnostics leads the operating picture

Diagnostics was Abbott's fastest-growing major business in the second quarter, with reported sales up 42.3 percent to USD 3.092 billion. Medical Devices sales increased 9.0 percent to USD 5.853 billion, while Established Pharmaceuticals sales rose 8.4 percent to USD 1.499 billion.

Nutrition was the counterweight, with worldwide sales down 3.1 percent to USD 2.144 billion in the quarter. That split makes the October report important for judging whether device and diagnostics growth can offset pressure in nutrition.

Analysts see room above the share price

Rothschild & Co Redburn upgraded Abbott from Neutral to Buy and raised its target from USD 119 to USD 127 on October 2, 2026, according to MarketBeat. The revised target lies 27.9 percent above the October 6 trading price.

MarketBeat reports a Moderate Buy consensus from 27 analysts, including 20 Buy, three Strong Buy and four Hold ratings. The average 12-month target is USD 119.80, which lies 20.6 percent above USD 99.33.

Abbott Laboratories stock stays below its yearly high

Abbott Laboratories stock had a market capitalization of USD 171.9 billion on October 6, 2026, with volume at 1,503,522 shares. Its NYSE 52-week range was USD 81.97 to USD 135.13, leaving the share closer to its yearly low than its yearly high despite the guidance increase.